TrialProteomics. Clinical applications2022

Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.

Anneke D van Dijk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.